Expertise in
5
conditions

Dr. Hassan Alnuaimat

Intensive Care Medicine
Uf Health Medical Specialties-Medical Plaza
1549 Gale Lemerand Dr, 
Gainesville, FL 
Expertise in
5
conditions
Uf Health Medical Specialties-Medical Plaza
1549 Gale Lemerand Dr, 
Gainesville, FL 

Overview

Hassan Alnuaimat is an Intensive Care Medicine provider in Gainesville, Florida. Dr. Alnuaimat is highly rated in 5 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Interstitial Lung Disease, Pulmonary Veno-Occlusive Disease, Lung Transplant, and Endoscopy.

His clinical research consists of co-authoring 42 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Intensive Care Medicine

Licenses

Anesthesiology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Uf Health Medical Specialties-Medical Plaza
1549 Gale Lemerand Dr, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

42 Total Publications

Serpiginous-Like Choroiditis with ANCA-PR3 Vasculitis in a Patient from Endemic Country: A Complex Phenotypic, Immunological and Epidemiological Puzzle.
Serpiginous-Like Choroiditis with ANCA-PR3 Vasculitis in a Patient from Endemic Country: A Complex Phenotypic, Immunological and Epidemiological Puzzle.
Journal: Ocular immunology and inflammation
Published: December 10, 2024
Similar Doctors
Hiren Mehta
Expertise in
24
conditions
Dr. Hiren Mehta
Intensive Care Medicine
Expertise in
24
conditions
Dr. Hiren Mehta
Intensive Care Medicine

Uf Health Medical Lab-Shands Hospital

1600 SW Archer Rd, 
Gainesville, FL 
 (0.1 miles away)
352-273-8737
Languages Spoken:
English
See accepted insurances

Hiren Mehta is an Intensive Care Medicine provider in Gainesville, Florida. Dr. Mehta is highly rated in 24 conditions, according to our data. His top areas of expertise are Lung Nodules, Lung Cancer, Small Cell Lung Cancer (SCLC), Endoscopy, and Gastrostomy.

Expertise in
12
conditions
Dr. Ali Ataya
Intensive Care Medicine
Expertise in
12
conditions
Dr. Ali Ataya
Intensive Care Medicine

UF Health Pulmonary - Medical Specialties - Medical Plaza

1549 Gale Lemerand Dr, 
Gainesville, FL 
 (0.4 miles away)
352-273-8740
Languages Spoken:
English
See accepted insurances

Ali Ataya is an Intensive Care Medicine provider in Gainesville, Florida. Dr. Ataya is highly rated in 12 conditions, according to our data. His top areas of expertise are Pulmonary Alveolar Proteinosis, Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Lung Transplant, and Fasciotomy.

Expertise in
12
conditions
Dr. Borna Mehrad
Intensive Care Medicine
Expertise in
12
conditions
Dr. Borna Mehrad
Intensive Care Medicine

Uf Health Medical Specialties-Medical Plaza

1549 Gale Lemerand Dr, 
Gainesville, FL 
 (0.4 miles away)
352-273-8740
Languages Spoken:
English
See accepted insurances

Borna Mehrad is an Intensive Care Medicine provider in Gainesville, Florida. Dr. Mehrad is highly rated in 12 conditions, according to our data. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pneumonia, Lung Transplant, and Tissue Biopsy.

Frequently Asked Questions about Dr. Hassan Alnuaimat

How do I make an appointment with Dr. Hassan Alnuaimat?

You can book an appointment with Dr. Hassan Alnuaimat by calling their office at 352-265-8940. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hassan Alnuaimat a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hassan Alnuaimat is classified as an Distinguished expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hassan Alnuaimat specialize in?

While Dr. Hassan Alnuaimat is a Intensive Care Medicine, they have specific expertise in Pulmonary Hypertension, Interstitial Lung Disease, and Pulmonary Veno-Occlusive Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Hassan Alnuaimat participate in research or clinical trials?

Yes. Dr. Hassan Alnuaimat has published 42 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Hassan Alnuaimat's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hassan Alnuaimat accept my insurance?

Dr. Hassan Alnuaimat accepts most major insurance plans, including Humana. We recommend calling the office directly at 352-265-8940 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alnuaimat's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile